Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Gemcitabine Combined With Nivolumab in NSCLC
NCT04331626Phase 4Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04331626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331626.